grey arrow to go to previous Omnicell webpage or forward to next Omnicell pageBack to Press Release

March 20, 2017

Omnicell Supports Pharmacy Advancement through Unrestricted Grant

Download PDF

MOUNTAIN VIEW, Calif., March 20, 2017 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions and adherence tools for healthcare systems and pharmacies, today announced it is providing an unrestricted grant to the European Association of Hospital Pharmacists (EAHP) for the purpose of supporting hospital pharmacy advancement.

A key component of advancing pharmacy is enabling pharmacists to utilize automation to manage inventory, improve security and tracking, and reduce waste, all of which contribute to decreasing medication errors and increasing patient safety.

Patient safety is a key objective of both Omnicell and EAHP. As such, Omnicell will partner with EAHP, via this grant, to support their continuing goal of improving care and outcomes for patients in the hospital setting. EAHP is now working with its member country associations to implement the European Statements of Hospital Pharmacy within their countries. These statements express commonly agreed upon objectives that every European health system should aim for in the delivery of hospital pharmacy services. Omnicell recognizes the importance of these statements and the positive impact they can have on the European health systems.

"EAHP is committed to ensuring that European national health system pharmacies are equipped with the technology they need to reduce medication errors and increase patient safety," said Jennie De Greef, chief operating officer of EAHP. "We are pleased to have a partner like Omnicell who shares our dedication to this endeavor."

"Omnicell strongly believes that safety is paramount for any facility offering care and we are pleased to offer our support as a Corporate Partner to EAHP, whose main focus is patient safety," said Randall Lipps, chairman, president, CEO and founder of Omnicell. "We look forward to working with them to help achieve their objectives."

About Omnicell

Since 1992, Omnicell (NASDAQ: OMCL) has been inspired to create safer and more efficient ways to manage medications and supplies across all care settings. As a leader in medication and supply dispensing automation, central pharmacy automation, IV robotics, analytics software, and medication adherence and packaging systems, Omnicell is focused on improving care across the entire healthcare continuum—from the acute care hospital setting, to post-acute skilled nursing and long-term care facilities, to the patient's home.

Over 4,000 customers worldwide use Omnicell® automation and analytics solutions to increase operational efficiency, reduce medication errors, deliver actionable intelligence and improve patient safety.

Omnicell's innovative medication adherence solutions, used by over 32,000 institutional and retail pharmacies in North America and the United Kingdom, are designed to improve patient adherence to prescriptions, helping to reduce costly hospital readmissions.

Recent Omnicell acquisitions, including Ateb, add distinct capabilities, particularly in central pharmacy, IV robotics, and pharmacy software, creating the broadest medication management product portfolio in the industry.

For more information about Omnicell, Inc. please visit


Editor's Notes:

  1. All Omnicell news releases (financial, acquisitions, products, technology etc.) are issued exclusively by PR Newswire and are immediately thereafter posted on the company's external website,
  2. Omnicell and the Omnicell logo design are registered trademarks of Omnicell, Inc.
  3. All other brand or product names may be trademarks or registered trademarks of their respective companies.


To view the original version on PR Newswire, visit:

SOURCE Omnicell, Inc.

News Provided by Acquire Media